Effects of canrenone in patients with metabolic syndrome

Giuseppe Derosa, Aldo Bonaventura, Lucio Bianchi, Davide Romano, Angela D'Angelo, Elena Fogari, Pamela Maffioli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults. Objectives: The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome. A total of 145 patients were treated with placebo or canrenone, 50 mg/day, for 3 months and then 50 mg b.i.d. till the end of the study. Blood pressure, body weight, body mass index, fasting plasma glucose (FPG), fasting plasma insulin, HOMA-IR, lipid profile, plasma aldosterone, brain natriuretic peptide, high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α) and M value were evaluated. Results: A decrease of blood pressure was observed in canrenone group compared to baseline; moreover, systolic blood pressure value recorded after 6 months of canrenone therapy was lower than the one recorded with placebo. Canrenone gave a significant decrease of FPI and HOMA index, and an increase of M value both compared to baseline and to placebo. Canrenone also decreased triglycerides and FPG was not observed with placebo. Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-α compared to baseline and to placebo. Conclusion: Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients.

Original languageEnglish
Pages (from-to)2161-2169
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number16
DOIs
Publication statusPublished - 2013

Fingerprint

Canrenone
Placebos
Blood Pressure
Fasting
Aldosterone
C-Reactive Protein
Tumor Necrosis Factor-alpha
Glucose
Brain Natriuretic Peptide
Insulin Resistance
Triglycerides
Body Mass Index
Obesity
Body Weight
Insulin
Lipids

Keywords

  • Aldosterone
  • Brain natriuretic peptide
  • Canrenone
  • Inflammation
  • Metabolic syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Effects of canrenone in patients with metabolic syndrome. / Derosa, Giuseppe; Bonaventura, Aldo; Bianchi, Lucio; Romano, Davide; D'Angelo, Angela; Fogari, Elena; Maffioli, Pamela.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 16, 2013, p. 2161-2169.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Bonaventura, Aldo ; Bianchi, Lucio ; Romano, Davide ; D'Angelo, Angela ; Fogari, Elena ; Maffioli, Pamela. / Effects of canrenone in patients with metabolic syndrome. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 16. pp. 2161-2169.
@article{bf0aa90aff994e50a9b9db83247a48bc,
title = "Effects of canrenone in patients with metabolic syndrome",
abstract = "Background: Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults. Objectives: The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome. A total of 145 patients were treated with placebo or canrenone, 50 mg/day, for 3 months and then 50 mg b.i.d. till the end of the study. Blood pressure, body weight, body mass index, fasting plasma glucose (FPG), fasting plasma insulin, HOMA-IR, lipid profile, plasma aldosterone, brain natriuretic peptide, high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α) and M value were evaluated. Results: A decrease of blood pressure was observed in canrenone group compared to baseline; moreover, systolic blood pressure value recorded after 6 months of canrenone therapy was lower than the one recorded with placebo. Canrenone gave a significant decrease of FPI and HOMA index, and an increase of M value both compared to baseline and to placebo. Canrenone also decreased triglycerides and FPG was not observed with placebo. Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-α compared to baseline and to placebo. Conclusion: Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients.",
keywords = "Aldosterone, Brain natriuretic peptide, Canrenone, Inflammation, Metabolic syndrome",
author = "Giuseppe Derosa and Aldo Bonaventura and Lucio Bianchi and Davide Romano and Angela D'Angelo and Elena Fogari and Pamela Maffioli",
year = "2013",
doi = "10.1517/14656566.2013.832756",
language = "English",
volume = "14",
pages = "2161--2169",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - Effects of canrenone in patients with metabolic syndrome

AU - Derosa, Giuseppe

AU - Bonaventura, Aldo

AU - Bianchi, Lucio

AU - Romano, Davide

AU - D'Angelo, Angela

AU - Fogari, Elena

AU - Maffioli, Pamela

PY - 2013

Y1 - 2013

N2 - Background: Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults. Objectives: The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome. A total of 145 patients were treated with placebo or canrenone, 50 mg/day, for 3 months and then 50 mg b.i.d. till the end of the study. Blood pressure, body weight, body mass index, fasting plasma glucose (FPG), fasting plasma insulin, HOMA-IR, lipid profile, plasma aldosterone, brain natriuretic peptide, high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α) and M value were evaluated. Results: A decrease of blood pressure was observed in canrenone group compared to baseline; moreover, systolic blood pressure value recorded after 6 months of canrenone therapy was lower than the one recorded with placebo. Canrenone gave a significant decrease of FPI and HOMA index, and an increase of M value both compared to baseline and to placebo. Canrenone also decreased triglycerides and FPG was not observed with placebo. Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-α compared to baseline and to placebo. Conclusion: Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients.

AB - Background: Metabolic syndrome is becoming a common disease due to a rise in obesity rates among adults. Objectives: The aim was to evaluate the effects of canrenone compared to placebo on metabolic and inflammatory parameters in patients affected by metabolic syndrome. A total of 145 patients were treated with placebo or canrenone, 50 mg/day, for 3 months and then 50 mg b.i.d. till the end of the study. Blood pressure, body weight, body mass index, fasting plasma glucose (FPG), fasting plasma insulin, HOMA-IR, lipid profile, plasma aldosterone, brain natriuretic peptide, high-sensitivity C-reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α) and M value were evaluated. Results: A decrease of blood pressure was observed in canrenone group compared to baseline; moreover, systolic blood pressure value recorded after 6 months of canrenone therapy was lower than the one recorded with placebo. Canrenone gave a significant decrease of FPI and HOMA index, and an increase of M value both compared to baseline and to placebo. Canrenone also decreased triglycerides and FPG was not observed with placebo. Canrenone also decreased plasma aldosterone, Hs-CRP and TNF-α compared to baseline and to placebo. Conclusion: Canrenone seems to be effective in reducing some factors involved in metabolic syndrome and in improving insulin-resistance and the inflammatory state observed in these patients.

KW - Aldosterone

KW - Brain natriuretic peptide

KW - Canrenone

KW - Inflammation

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84885676827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885676827&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.832756

DO - 10.1517/14656566.2013.832756

M3 - Article

VL - 14

SP - 2161

EP - 2169

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -